Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) announced preliminary unaudited revenue figures for Q4 and the full year 2021, predicting revenues of approximately $0.362 to $0.437 million for Q4 and $1.42 to $1.50 million for the entire year. The company also secured $0.81 million in grant funding for Q4 and $1.45 million for the year. Despite challenges, Hyperfine installed over 50 Swoop devices in 2021, emphasizing growth potential in portable MRI technology.
Hyperfine (Nasdaq: HYPR) announces its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. ET. The company, known for its FDA-cleared portable MRI system Swoop®, strives to enhance patient access to diagnostic imaging. Interested parties can view the live and archived presentation on the company's investor website. The Swoop system enables rapid scans directly at the patient's bedside, providing critical imaging at a lower cost, making it a valuable tool for emergency departments, operating rooms, and intensive care units.
Hyperfine Inc. has completed its business combination with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ), securing approximately $160 million in gross cash proceeds. This funding aims to accelerate the growth initiatives for its Swoop® portable MRI system, designed to enhance patient access to MRI technology. Trading under the ticker HYPR will commence on December 23, 2021. Hyperfine focuses on transforming medical imaging with Swoop, aiming to expand both domestically and internationally while addressing healthcare disparities.
Hyperfine and Liminal announced a definitive agreement for a business combination with HealthCor Catalio Acquisition Corp (Nasdaq: HCAQ). This merger creates a combined company valued at approximately $580 million, with expected cash resources around $375 million. The transaction aims to enhance accessibility and affordability in MRI imaging through Hyperfine's FDA-cleared Swoop™ device and Liminal's brain monitoring innovations. The merger is anticipated to close in Q4 2021, pending shareholder approvals and customary conditions.